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Introduction
Amyloid light chain (AL) amyloidosis is caused by clonal
lambda or kappa restricted bone marrow plasma cell prolifer-
ation, producing amyloidogenic light chains. Deposition of
amyloid fibrils causes progressive organ failure, which even-
tually leads to death. The primary goal of therapy in systemic
amyloidosis is to eliminate the supply of precursor protein
and thereby stop further amyloid deposition.1 Many treat-
ment options are currently available, including proteasome
inhibitors, immunomodulatory drugs (IMIDS) and high-dose
chemotherapy.2 Recently, Palladini et al. reported the results in
259 patients of risk-adapted melphalan-dexamethasone
which induced a high rate of hematologic response (76%)
and complete remissions in 31% of cases.3 The median over-
all survival was 7.4 years in the patients that could tolerate
high-dose dexamethasone. The role of high-dose melphalan
(HDM) and autologous stem cell transplantation (ASCT) is a
subject of debate. Although extended survival can be
obtained with ASCT,2 data on the efficacy are scarce and
almost all data are retrospective.4-6 No survival benefit was
found for ASCT in a recent meta-analysis of 12 studies.7
Moreover, in the randomized trial of the French Myeloma
Collaborative Group, auto-SCT was not found to improve
survival as compared to melphalan-dexamethasone.8 A major
limitation of the French study was the high incidence of non-
relapse mortality (NRM; 24%) of HDM (the majority of
patients received 200 mg/m2) and ASCT given as front-line
therapy. We hypothesized that a 2-step approach consisting
of induction therapy followed by HDM would improve the
overall response rate and subsequent survival. An important
aspect of this approach is that effective induction therapy
may increase  the number of patients eligible for intensifica-
tion and will reduce NRM. Here, we present the extended fol-
low up of our prospective study after a median follow up of
115 months.  
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In a prospective multicenter phase II study, we evaluated the effect of three courses of vincristine, doxorubicin and
dexamethasone followed by high-dose melphalan and autologous stem cell transplantation on an intention-to-
treat basis. Sixty-nine newly diagnosed patients with amyloid light chain amyloidosis were included between
November 2000 and January 2006: 37 men and 32 women with a median age of 56 years, including 46% of
patients with cardiac and 22% of patients with involvement of 3 or 4 organs. Initial results presented in 2008
showed a 4-year overall survival rate of 62% among all the patients, while the 4-year survival rate after transplan-
tation was 78%. Here we report the long-term follow-up data after a median follow up of 115 months of the
patients still alive. Median survival of all patients was 96 months from registration and for the transplanted
patients ten years from the date of transplantation. Twelve (12%) patients died during induction therapy with vin-
cristine, doxorubicin and dexamethasone, including 8 patients (12%) due to treatment-related mortality. Two
patients died within one month following high-dose melphalan. We conclude that vincristine, doxorubicin and
dexamethasone should not be applied as induction therapy for intensification in amyloid light chain amyloidosis.
However, a 2-step approach consisting of a non-intensive less toxic induction therapy followed by high-dose mel-
phalan and autologous stem cell transplantation may result in extended survival in newly diagnosed patients with
amyloid light chain amyloidosis (clinicaltrials.gov identifier: 01207094). 
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ABSTRACT
Methods
Study design and end points
In this prospective multicenter phase II study, the effect of three
courses of vincristine, doxorubicin, dexamethasone (VAD) admin-
istered as rapid infusion9,10 followed by HDM with ASCT was
evaluated in AL amyloidosis. Patients who did not meet the eligi-
bility criteria for HDM after VAD went off protocol treatment and
were followed for survival. Study end points were efficacy with
regard to response rate, overall survival, feasibility and the value of
risk factors at diagnosis. The trial was carried out in accordance
with the Declaration of Helsinki. The protocol was approved by
the Institutional Review Boards of all participating hospitals, and
all patients provided written informed consent before inclusion in
the study. 
Patients and evaluation of organ involvement
Patients under 66 years of age with biopsy-proven AL amyloi-
dosis and monoclonal gammopathy or Durie & Salmon multiple
myeloma stage I were included (n=16, 23%). Patients were either
treatment naïve or had previously been treated with a maximum
three courses of melphalan and prednisone. Patients with prior
malignancy diagnosed less than five years ago [except non-
melanoma skin tumors or stage 0 (in situ) cervical carcinoma],
other types of amyloidosis, and severe other pulmonary, neurolog-
ical, psychiatric, cardiac, liver or metabolic diseases not related to
AL amyloidosis were excluded. Patients’ characteristics are sum-
marized in Table 1
Amyloid was diagnosed by apple green birefringence in polar-
ized light of a Congo red-stained biopsy of heart, kidney, liver, gut,
nerve, or abdominal fat tissue. All patients with AL amyloidosis
should have signs of a clonal plasma cell dyscrasia by immunoelec-
trophoresis, free light chain in serum or urine, or immunopheno-
typing of plasma cells in bone marrow. In patients with isolated
nephropathy or gastroenteropathy, or an underlying inflammatory
condition, AA amyloid had to be excluded by immunohistochem-
istry. In patients with isolated cardiomyopathy or neuropathy, or
a positive family history ATTR amyloid, had to be excluded by
immunohistochemistry and by DNA analysis of the TTR gene.
Definition of major organ involvement 
Renal involvement: defined as proteinuria more than 0.5 g/24 h or
serum creatinine more than 106 mmol/L (or an endogenous creati-
nine clearance below 90 mL/min) in the absence of other causes of
renal disease.
Cardiac involvement: defined as the presence of a mean left ven-
tricular wall thickness on cardiac ultrasound more than 11 mm in
the absence of a history of hypertension or valvular heart disease
or as the presence of unexplained low voltage (<0.5 mV) on the
electrocardiogram or by congestive heart failure as per NYHA
heart failure class. Patients who were NYHA class 1 with evidence
of cardiac amyloid by echocardiogram or electrocardiogram were
categorized as having asymptomatic cardiac involvement. Patients
who were NYHA class 2 or higher with evidence of cardiac
involvement were categorized as having predominant cardiac
involvement (amyloid cardiomyopathy).
Hepatic involvement: defined as hepatomegaly (liver span >15 cm)
or alkaline phosphatase more than 200 U/L in the absence of other
causes of liver disease. Peripheral polyneuropathy was defined as
the typical complaints of sensory or motor neuropathy and con-
firmed by a neurologist. 
Autonomic neuropathy: defined as the presence of orthostatic
hypotension (a drop in systolic blood pressure of 20 mm Hg or
more and a drop in diastolic blood pressure of 10 mm Hg or more
and a rise in heart rate of 10 or less beats per minute during the
first three minutes after a change from the supine to the upright
posture) or abnormal autonomic testing by the method of Ewing
and Clark (score >5 points) not caused by medication. 
Gastrointestinal tract: defined by positive biopsy combined with
symptoms.
Soft tissue: defined by tongue enlargement, arthropathy, skin,
myopathy by biopsy or pseudohypertrophy, lymph node (may be
localized), carpal tunnel syndrome all combined with an AL amy-
loid positive biopsy.
In the final analysis, high-risk patients were defined retrospec-
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Table 1. Characteristics at entry of 69 patients with AL amyloidosis.
Characteristics                                                                  Number (%) 
                                                                                           or median 
                                                                                             (range)
Age (years)                                                                                         56 (25-65)
Male : female                                                                              37 : 32 (54% : 46%)
Clonal disease                                                                                             
Serum M-protein                                                                            60 (87%)
Kappa : lambda                                                                  15 : 46 (22% : 67%)
Urine Bence Jones (g/L) (n=25)                                             0.1 (0-42)
Bone marrow clonal plasma cells                                               50 (72%)
Kappa : lambda                                                                 11 : 39 (16% : 57%)
Plasma cells in smears (%)                                                    7 (0-28)
Multiple myeloma stage I                                     
WHO performance status                                                                16 (23%)
0                                                                                                           26 (38%)
1                                                                                                           34 (49%)
2                                                                                                            7 (10%)
3                                                                                                             1 (1%)
Unknown                                                                                              1 (1%)
Major organ involvement                                                                          
Kidney                                                                                                58 (84%)
Heart                                                                                                  32 (46%)
Liver                                                                                                    12 (17%)
Nerve (peripheral and/or autonomic)                                       18 (26%)
Gastrointestinal                                                                                 2 (3%)   
Soft tissue                                                                                         8 (11%)
Macroglossia                                                                                   6 (9%)
Lymph node, lung                                                                           1 (1%)
Shoulder pads, muscle                                                                 1 (1%)
Other organ involvement                                                                 29  (42%)
Bone marrow biopsy positive                                                        15 (22%)
CTS                                                                                                      10 (14%)
Splenomegaly                                                                                     3 (4%)
Miscellaneous*                                                                                  1(1%)
Number of major organs involved (0-4)                                               
0                                                                                                           1  (1%)*
1                                                                                                           30 (43%)
2                                                                                                           23 (33%)
3                                                                                                           13 (19%)
4                                                                                                             2 (3%)
Biochemical measurements, median (range)                                    
Creatinine (mmol/L) (n=69)                                                     92 (55-639)
Creatinine clearance (mL/min) (n=22)                                 72 (10-124)
Urinary protein (g/24h) (n=47)                                                2.6 (0-17.9)
Alkaline phosphatase (U/L) (n=66)                                      102 (34-3263)
Bilirubin (mmoL/L) (n= 59)                                                         6 (0-134)
Albumin (g/L) (n= 65)                                                               28.4 (13-51.5)
β-2-microglobulin (mg/L) (n= 47)                                          2.60 (0-10.4)
High-risk patients (n=47)                                                                37 (79%)
Miscellaneous*: Factor X deficiency.
tively as having one or more of the following major risk factors:
cardiac septum thickness 15 mm or more, cardiac ejection fraction
55% or less, serum creatinine more than 177 mmol/L, or serum
bilirubin more than 34 mmol/L, while patients were considered
low risk if all four risk factors were absent. 11
Treatment
The VAD regimen could be modified in case of risk of enhanced
toxicity. Vincristine was not used in patients with more than grade
2 neuropathy (neurosensory, neuromotory) and in patients with
signs of autonomic neuropathy. Dexamethasone only, according
to the above schedule, was given in patients with WHO perform-
ance status 4, severe cardiac disease (NYHA grade 4 heart failure
or cardiac ejection fraction <45% or mean left ventricular wall
thickness on echocardiogram >15 mm or syncope caused by dys-
rythmia or severe conduction defect), or inadequate liver function
probably related to AL amyloidosis, i.e. bilirubin 2.5 times the
upper normal value. Supportive care during VAD consisted of
pneumococcal and pneumocystis prophylaxis with cotrimoxazol
2x480 mg daily, prophylaxis of infections in case of severe neu-
tropenia (ANC< 0.5x109/L), fluconazole 50 mg daily, and antacids
(or otherwise according to local protocols).
Patients were re-evaluated after the third course and judged eli-
gible for stem cell collection and ASCT if WHO performance sta-
tus was grade 0-2, NYHA class was grade 1-3, cardiac ejection
fraction was more than 45%, absence of active infections, absence
of severe pulmonary, neurological and psychiatric disease, the
serum bilirubin and transaminase concentrations not exceeding
2.5 times the upper reference limit, and normal blood counts
(WBC ≥2x109/L and platelets >100x109/L).
Autologous PBSC were collected at day 4 or 5 after granulocyte-
colony stimulating factor (G-CSF) at a dose of 10 mg/kg. High-dose
melphalan and ASCT started between 2-6 weeks after stem cell
collection. Melphalan 100 mg/m²/day was given as rapid infusions
on days -3 and -2. In patients with a creatinine clearance of 40
mL/min or less, melphalan 100 mg/m² was administered on day -
2 only.
Treatment response and outcome evaluation
The main end points were hematologic and clinical response,
the percentage of patients that ultimately received HDM and
ASCT, and overall survival.
Hematologic response was defined as complete response (disap-
pearance of monoclonal protein in blood and urine, and no excess
of clonal of plasma cells in bone marrow), partial response (>50%
reduction in serum and urine monoclonal proteins), persistence,
relapse (recurrence of monoclonal protein after complete
response), and progression (doubling of monoclonal protein in
serum or urine).
Organ response was retrospectively defined according to the
published guidelines as per the Tenth International Symposium on
Amyloidosis.11 Grading of toxicity and adverse events was per-
formed using the NCI Common Terminology Criteria for Adverse
Events (CTCAE, version 3.0, published December 12, 2003).  
Statistical analysis
It was intended that 60 patients would be included in this trial,
with interim analyses after the first 20 and 40 patients, with the
possibility of discontinuing the trial early when the true percent-
age of transplanted patients would be 20% or less. The percentage
of patients ultimately transplanted was considered to be the most
relevant end point for early discontinuation of the study. It was
expected that approximately one-third of the patients would
receive an autologous transplant. Should this be less than 20%, the
study should be considered for early discontinuation. A multiple-
stage procedure12 was used with two interim analyses after 20 and
40 evaluable patients with the possibility of early discontinuation.
The stopping rules were determined in such a way that the prob-
ability of early stopping was small if the true percentage of trans-
planted patients was 35% or more, while there would be a con-
siderable probability that the trial would be stopped early if the
true percentage of transplanted patients was 20% or less.
If the true percentage of transplanted patients were 20%, there
would be a probability of 41% to discontinue the trial after reach-
ing 20 evaluable patients, while the probability of (undeserved)
early discontinuation would be only 4% if the true percentage of
transplanted patients were 35%. So the null hypothesis was that
the proportion of transplanted patients would be 20% or less,
while the alternative hypothesis is that this proportion would be
35% or more.The actuarial Kaplan-Meier method was used to cal-
culate overall survival (OS) of all patients from registration until
death from any cause, and for the transplanted patients OS from
the date of transplantation until death. Patients still alive or lost to
follow up were censored at the last day they were known to be
alive. As exploratory analyses, univariate logistic regression was
used to evaluate the association of base-line characteristics (sex,
age, number of renal/cardiac/hepatic/neurologic organs involved
(0-2 vs. 3-4), and risk score (low vs. high) with the probability of
receiving an autologous transplant, while univariate Cox regres-
sion analysis was used to evaluate the association of these base-
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haematologica | 2015; 100(5) 679
Figure 1. Kaplan-Meier survival curve showing overall survival in
months of study group. (A) From registration in the study. (B) From
autologous stem cell transplant (ASCT). N: number of patients; d:
number of deaths.
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line characteristics with OS from registration and OS from trans-
plantation. P values have not been corrected for multiple testing,
and a two-sided significance level α=0.05 was used.
Results
Patients’ characteristics
Seventy patients with AL amyloidosis were included in
the study between November 2000 and January 2006.
One patient was ineligible (no MGUS, nor MM stage 1)
and was excluded from all further analyses. The reason for
extending the inclusion to 69 patients (60 intended) was
the intention to start a follow-up trial. However, that took
longer than expected and it was decided to close the trial
on February 1, 2006. 
Characteristics of the 69 eligible patients are shown in
Table 1. Forty-four patients were in NYHA class 1 (64%),
12 were in class 2 (17%), 10 were in class 3 (14%), 2 were
in class 4 (3%), and classification was missing for one. Left
ventricular wall thickness was median 13 mm (range 7-30
mm), cardiac ejection fraction was median 61% (range
20%-89%), and low voltage ECG was present in 11
patients (16%). Lung diffusion abnormalities were found
in 8 patients (12%). Fifty-eight (84%) had renal involve-
ment; however, none of these patients were dialysis
dependent at diagnosis or at transplant. Of 47 patients
with available data, 37 (79%) could retrospectively be
classified as high-risk patients.11  
VAD treatment and stem cell collection preceding HDM
and ASCT
Seven patients received pre-treatment before study
inclusion. Previous treatment consisted of 1-4 days of dex-
amethasone in 4 patients, 2-3 cycles of melphalan and
prednisolone in 2 patients, and 4 days prednisolone and
cyclophosphamide in another patient.
Ten patients received only one cycle of VAD, 5 patients
received two cycles of VAD, and 54 patients received
three cycles of VAD. The dose of vincristine was reduced
in 2 patients and was not given in 15 patients. The dose of
doxorubicin was reduced in 3 patients and was not given
in 5 patients. The dose of dexamethasone was reduced in
5 patients and was not given in one patient.
Stem cells were mobilized and collected in 46 patients
(67%) who could proceed to HDM after VAD induction.
Mobilization started median 104 days after registration
(range 83-193 days). G-CSF was used in 45 patients and
cyclophosphamide in 4 patients. The number of collected
stem cells was median 5.1x106 CD34/kg (range 2.1-
17.3xCD34/106/kg). 
High-dose melphalan and autologous stem cell 
transplantation
High-dose melphalan was administered median 141
days after registration (range 87-224 days). Thirty-four
patients (74%) received full dose (200 mg/m2) melphalan,
one received 140 mg/m2, 9 received 100 mg/m2, and 2
patients received 70 mg/m2. The treating physicians’ rea-
sons for the divergent dosages administered were cardiac
insufficiency, WHO performance status 2, and renal insuf-
ficiency, respectively. Twenty-three patients were not
transplanted: 11 patients died during/after VAD, 7 patients
were not eligible for mobilization, 3 patients refused, and
2 patients had progressive disease. The stem cell trans-
plants were performed in 10 transplantation centers in the
Netherlands and in one Belgian center. Median infused
number of stem cells was 3.6x106 CD34/kg (range 0.4-
28.0x106 CD34/kg). Median time of hospital care was 21
days (range 0-86 days). Median number of platelet trans-
fusions was 2 (range 0-38) and median number of red
blood cell units was 3 (range 0-24). Median hematologic
recovery time of ANC more than 1.0x109/L and platelets
more than 50x109/L was 17 and 21 days, respectively.
Treatment-related mortality and toxicity
VAD chemotherapy: 12 patients (18%) died during induc-
tion therapy with VAD. Causes of death were heart and
neurological toxicity in 2 patients, cardiac in 2, infectious
in 2, unknown in 2, and amyloidosis in 4 patients. Seven
of the 12 patients had cardiac involvement; of these, 5
patients had involvement of 3 major organs. Side-effects
CTC grade 2 or over were recorded in 46%, 49%, and
48% of patients during each of the respective three cycles
of VAD induction. Side-effects were diverse, but most fre-
quent were gastrointestinal, cardiovascular function, and
neurological problems. Infections CTC grade 2 or over
were recorded in 13%. 
Stem cell mobilizing chemotherapy and leukapheresis:
no patient died during or after stem cell mobilization and
leukapheresis. Side-effects CTC grade 2 or over were
recorded in 15% of patients; infections CTC grade 2 or
over were recorded in 9%.
High-dose melphalan and autologous stem cell transplanta-
tion: 2 of the 46 patients (4%) died from treatment-related
mortality (TRM) within 100 days after administration of
HDM; at day 1 from a cardiac cause and one after one
month from combined renal and cardiac failure, respec-
tively.  Side-effects CTC grade 2 or over were recorded in
87% of patients after HDM and infections CTC grade 2 or
over were recorded in 65%.  Of the 32 women, 28 (88%)
received ASCT, in contrast to only 18 of 37 (49%) male
patients (P<0.01). Forty-three of 54 (80%) patients with 0-
2 major risk factors were transplanted versus only 3 of 15
(20%) with 3-4 major risk factors (P<0.001). Furthermore,
while all 10 patients with low risk were transplanted, only
20 of 37 (54%) with high-risk disease received ASCT
(P<0.01; Fisher exact test).11
Treatment response 
Survival: median OS of all patients from registration was
90 months; the 1-year, 5-year and 10-year OS were 70%,
54% and 34%, respectively (Figure 1A). All 23 patients
who did not receive HDM have died (median OS was 3
months; max. 112). Median follow up after HDM and
ASCT in 25 patients still alive is 115 months from inclu-
sion and 111 months from ASCT. The 1-year OS for
patients from transplantation was 93%, while the 5-year
OS was 74%, and the 10-year OS was 51%. Median sur-
vival in this group is 122 months (Figure 1B). Male sex and
3-4 major organs involved were also associated with
worse overall survival from registration. Also the survival
of the 9 patients with previous treatment (usually dexam-
ethasone or MP) was significantly worse than the 60
patients without previous treatment (median OS 14 vs.
101 months; P=0.004). The outcome of the 16 patients (of
whom 9 were transplanted) with AL amyloidosis and
stage I MM was not statistically different although their
survival tended to be shortened [hazard ratio (HR) 1.87,
B.P.C. Hazenberg et al.
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95%CI: 0.97-3.60; P=0.07]. Among the transplanted
patients, sex, age, 3-4 major organs, high risk were not sig-
nificantly associated with OS from transplantation; how-
ever, the median OS was 93 months in the high-risk
patients versus 122 months in low-risk (P=0.12). 
Hematologic response of plasma cell disease: overall hemato-
logic response after the third cycle of VAD was achieved
in 16 patients (23%) of whom 4 patients (6%) had a com-
plete response. Twenty-one patients (46%) obtained an
overall hematologic response after ASCT, including 6
patients (13%) with a CR. Stable persistent disease was
seen in 8 patients (17%) and response status was not
assessed in 17 patients (37%).  
Clinical response: overall clinical improvement after the
third cycle of VAD was present in 11 (16%) patients (6
renal, 1 cardiac, 0 hepatic, 4 neuropathic, 1 albumin, and 4
other improvement). Overall clinical improvement after
stem cell transplantation was present in 19 (41%) patients
(8 renal, 1 cardiac, 2 hepatic, 4 neuropathic, 6 albumin, and
7 other improvement), stabilization was seen in 14 (30%)
patients, progression in 10 patients, and unknown in 3
patients. 
Discussion
Long-term follow up of our prospective study shows
that a 2-step approach of induction therapy followed by
ASCT results in prolonged survival in AL amyloidosis;
however, patients who qualified for the intensification
phase benefitted most. Median survival on an intention-
to-treat basis was 90 months and 122 months for the
ASCT patients. VAD treatment did not affect stem cell
mobilization and 67% of the patients could proceed to
HDM and ASCT, which was associated with low TRM
(4%). However, initial mortality during VAD was high
(18%), indicating toxicity of this regimen in AL amyloido-
sis. It should be noted, however, that high-risk patients
with multi-organ involvement were not excluded from
our study. Increased toxicity of VAD as induction to auto-
SCT was also found by Perz et al. with 25% of patients
experiencing grade 3-4 toxicity and a 7% mortality.13 We
must conclude that VAD should not be given to patients
with AL amyloidosis. 
A limitation of this evaluation is that the study was per-
formed between 2000-2006. We did not have the avail-
ability of cardiac biomarkers and serum free light chains,
which are now considered the most important prognostic
factors for survival, and also since then new consensus
response criteria have been introduced.14-17 Other limita-
tions are the high numbers of patients without an assessed
hematologic (37%) and clinical response (also 37%), partly
explained by the strict requirements of our response crite-
ria, e.g. repeated bone marrow investigation. 
The debate about the role of ASCT for AL amyloidosis
will continue. Being eligible for ASCT is probably one of
the most important favorable prognostic factors.14,18,19 In
our prospective trial, median overall survival was 10.1
years in the patients who underwent auto-SCT versus only
a median three months for the patients who were not able
to undergo the transplant, mainly due to early death.
A major challenge remains the treatment of high-risk dis-
ease. Only a minority of our patients with 3-4 risk factors
could proceed to ASCT. More effective and less toxic regi-
mens than VAD are nowadays available for the treatment of
AL amyloidosis that can also be used as induction before
auto-SCT.20-25 In our study, hematologic response was 23%
after VAD and 48% after HDM and ASCT.  Novel anti-MM
regimens, including bortezomib, induce impressive response
rates (>90%) of excellent quality which lead to a high per-
centage of complete remissions (up to 70%) following inten-
sification in younger patients with MM.26,27 It is likely that
with such induction regimens high-risk patients are stabi-
lized more rapidly and have a greater chance of improve-
ment of their organ damage and performance status. This
will qualify a higher percentage of patients eligible for sub-
sequent intensification. As complete eradication of the amy-
loid producing clone may be the best prerequisite for
improvement of AL amyloid-related symptoms and survival
in standard and high-risk patients, we are in favor of contin-
uing a 2-step approach for treatment of younger AL amyloi-
dosis patients. Preliminary data from a study in patients
with renal amyloidosis comparing bortezomib/dexametha-
sone followed by auto-SCT with auto-SCT alone seem to
confirm the rationale of such a 2-step approach.28 This design
with bortezomib/dexamethasone induction followed by
HDM 200 and ASCT is also prospectively explored in a col-
laborative study of HOVON and the German Amyloidosis
Center in Heidelberg, Germany (registered at www.trialregis-
ter.nl; NTR3220). 
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